The role of CD300LD in the suppression of the immune system through tumors: new knowledge for cancer therapy

Veröffentlicht:

Aktualisiert:

Von:

Titel: Neue Studie identifiziert vielversprechendes Zielmolekül zur Krebstherapie Untertitel: CD300ld als entscheidende Immunhemmer-Komponente auf polymorphonuklearen myeloid-abgeleiteten suppressor Zellen (PMN-MDSCs) entdeckt Einleitung: Eine bahnbrechende neue Studie hat das Potenzial, die Wirksamkeit von Immuntherapien gegen Krebs deutlich zu verbessern. Die Forschungsergebnisse, veröffentlicht in der renommierten Fachzeitschrift „Nature“, beleuchten die Rolle von CD300ld, einem Molekül, das auf polymorphonuklearen myeloid-abgeleiteten suppressor Zellen (PMN-MDSCs) zu finden ist. Diese Zellen spielen eine entscheidende Rolle im Tumormikroenvironment und tragen zur Tumorentwicklung und -therapieresistenz bei. Herausforderung des immununterdrückenden Tumormikroenvironments: Effektive Immuntherapien zur Behandlung von Krebs stehen vor einer großen Herausforderung: dem immununterdrückenden Tumormikroenvironment. Eine genaue Identifizierung der Schlüsselmoleküle …
Title: New study identifies promising target molecule for cancer therapy Subtitles: CD300LD as a decisive immune-inmmer component on polymorphonuclear myeloid-derived Suppressor Cells (PMN-MDSCs) Discovered Introduction: A groundbreaking new study has the potential to significantly improve the effectiveness of immunotherapies against cancer. The research results, published in the renowned trade magazine "Nature", illuminate the role of CD300LD, a molecule that can be found on polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). These cells play a crucial role in tumor microenvirte and contribute to tumor development and therapy resistance. The challenge of the immune -suppressing tumor microenvironment: Effective immunotherapies for the treatment of cancer face a major challenge: the immune -suppressing tumor microenvirte. A precise identification of the key molecules ... (Symbolbild/natur.wiki)

Title: New study identifies promising target molecule for cancer therapy

Subtitle: CD300LD as a decisive immune Hemmer component on polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCS) discovered

Introduction:
A groundbreaking new study has the potential to significantly improve the effectiveness of immunotherapy against cancer. The research results, published in the renowned trade magazine "Nature", illuminate the role of CD300LD, a molecule that can be found on polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). These cells play a crucial role in tumor microcroonment and contribute to tumor development and therapy resistance.

Challenge of the immune -suppressing tumor mroenvironment:
Effective immunotherapies for the treatment of cancer face a major challenge: the immune -suppressing tumor microenvirte. A precise identification of the key molecules on the PMN MDSCs is therefore of great importance to specifically address these cells for tumor therapy.

Results of the study:
The latest findings from experiments on tumor models show that CD300LD was identified as one of the most important target molecules on PMN-MDSCs. CD300LD is specifically expressed in normal neutrophil granulocytes and is increasingly present in the tumor-related context with PMN-MDSCs. By switching off the CD300LD molecule, the development of several cancer types could be inhibited in a PMN-MDSC-dependent manner.

In addition, the study showed that CD300LD is important for recruiting PMN-MDSCs in tumors and their oppressive function compared to T cell activation. CD300LD acts via the Stat3-S100A8/A9-axis and the switching off of the Gens CD300LD reverses the immune-suppressing tumor mroonation. Interestingly, an increased expression of CD300LD in human tumors, which had a negative impact on the survival of the patients.

Potential for cancer immunotherapy:
The blocking of the CD300LD activity showed promising results in the inhibition of tumor growth and synergistic effects in combination with anti-PD1 immunotherapy. The identification of CD300LD as a critical immune inhibitor on PMN-MDSCs opens up new perspectives for cancer immunotherapy.

Conclusion:
The latest research results underline the importance of CD300LD as a potential target molecule for the development of innovative immunotherapies against cancer. The promise of this findings is the possibility of specifically aligning immunotherapy on the suppressive properties of PMN-MDSCs and thus fighting tumor development and therapy resistance. Further examinations are required to use the full potential of CD300LD in cancer treatment.

Source: Nature Study-CD300LD AS A Critical Immune Suppressor on Polymorphonuclear Myeloid-Derived Suppressor Cells in Tumour Immune Resistance (http://www.nature.com/artics/s41586-06511-9)